ATE199553T1 - Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung - Google Patents

Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung

Info

Publication number: ATE199553T1
Authority: AT; Austria
Prior art keywords: compounds; alkyl; pct; trifluoromethyl; unsubstituted
Prior art date: 1994-09-29

Application number

AT95932693T

Other languages

English (en)

Inventor

Martin Missbach

Original Assignee

Novartis Erfind Verwalt Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-29

Filing date

1995-09-08

Publication date

2001-03-15

1995-09-08 Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh

2001-03-15 Application granted granted Critical

2001-03-15 Publication of ATE199553T1 publication Critical patent/ATE199553T1/de

Links

150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
125000000217 alkyl group Chemical group 0.000 abstract 4
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
101800003838 Epidermal growth factor Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940116977 epidermal growth factor Drugs 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Oncology (AREA)
Diabetes (AREA)
Neurology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Detergent Compositions (AREA)

AT95932693T 1994-09-29 1995-09-08 Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung ATE199553T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH295394		1994-09-29
PCT/EP1995/003536 WO1996010028A1 (en)	1994-09-29	1995-09-08	PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE

Publications (1)

Publication Number	Publication Date
ATE199553T1 true ATE199553T1 (de)	2001-03-15

Family

ID=4245363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95932693T ATE199553T1 (de)	1994-09-29	1995-09-08	Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung

Country Status (20)

Country	Link
US (1)	US5869485A (de)
EP (1)	EP0783505B1 (de)
JP (1)	JP4145955B2 (de)
KR (1)	KR970706288A (de)
CN (1)	CN1046731C (de)
AT (1)	ATE199553T1 (de)
AU (1)	AU694801B2 (de)
BR (1)	BR9509048A (de)
CA (1)	CA2200210A1 (de)
DE (1)	DE69520282T2 (de)
DK (1)	DK0783505T3 (de)
ES (1)	ES2157344T3 (de)
FI (1)	FI112867B (de)
GR (1)	GR3035996T3 (de)
HU (1)	HU222181B1 (de)
MX (1)	MX9702307A (de)
NO (1)	NO308108B1 (de)
NZ (1)	NZ293249A (de)
PT (1)	PT783505E (de)
WO (1)	WO1996010028A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
SI9620103A (sl) *	1995-07-06	1998-10-31	Novartis Ag	Pirolopirimidini in postopki za njihovo pripravo
AU3176297A (en) *	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
JP4056589B2 (ja) *	1996-07-19	2008-03-05	武田薬品工業株式会社	複素環化合物、その製造法および用途
US6211215B1 (en) *	1996-07-19	2001-04-03	Takeda Chemical Industries, Ltd.	Heterocyclic compounds, their production and use
WO1998007726A1 (en)	1996-08-23	1998-02-26	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
US6251911B1 (en)	1996-10-02	2001-06-26	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
GB9704948D0 (en)	1997-03-11	1997-04-30	Knoll Ag	Therapeutic agents
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
TR199902301T2 (xx) *	1997-03-19	1999-12-21	Basf Aktiengesellschaft	Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
CN1264381A (zh) *	1997-08-05	2000-08-23	辉瑞产品公司	4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
JP4611524B2 (ja) *	1998-06-02	2011-01-12	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6713474B2 (en)	1998-09-18	2004-03-30	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as therapeutic agents
ID29028A (id) *	1998-09-18	2001-07-26	Basf Ag	Pirolopirimidina sebagai penghambat protein kinase
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
JP2003509428A (ja)	1999-09-17	2003-03-11	アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー	治療薬としてのピラゾロピリミジン
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) *	2000-03-29	2001-10-08	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
US20040248906A1 (en)	2001-08-10	2004-12-09	Donato Nicholas J	Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
US6770652B2 (en) *	2001-10-18	2004-08-03	Duquesne University Of The Holy Ghost	Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE10163991A1 (de) *	2001-12-24	2003-07-03	Merck Patent Gmbh	Pyrrolo-pyrimidine
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
GB0226370D0 (en) *	2002-11-12	2002-12-18	Novartis Ag	Organic compounds
US7157460B2 (en) *	2003-02-20	2007-01-02	Sugen Inc.	Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
JP2007520559A (ja) *	2004-02-03	2007-07-26	アボット・ラボラトリーズ	治療薬としてのアミノベンゾオキサゾール類
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
ES2365869T3 (es) *	2005-11-17	2011-10-11	OSI Pharmaceuticals, LLC	COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
ES2545907T3 (es) *	2005-12-29	2015-09-16	Abbvie Inc.	Inhibidores de proteína quinasa
TW200738725A (en) *	2006-01-25	2007-10-16	Osi Pharm Inc	Unsaturated mTOR inhibitors
EP2276763A1 (de) *	2008-03-19	2011-01-26	OSI Pharmaceuticals, Inc.	Salzformen eines mtor-inhibitors
EP2358720B1 (de) *	2008-10-16	2016-03-02	The Regents of The University of California	Heteroarylkinasehemmer mit kondensierten ringen
WO2010066629A2 (en) *	2008-12-09	2010-06-17	F. Hoffmann-La Roche Ag	Novel azaindoles
CN102596963A (zh)	2009-09-10	2012-07-18	诺瓦提斯公司	二环杂芳基的醚衍生物
WO2011064211A1 (en)	2009-11-25	2011-06-03	Novartis Ag	Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
JP2013528635A (ja)	2010-06-17	2013-07-11	ノバルティスアーゲー	ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2011157793A1 (en)	2010-06-17	2011-12-22	Novartis Ag	Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
JP2014507465A (ja)	2011-03-08	2014-03-27	ノバルティスアーゲー	フルオロフェニル二環式ヘテロアリール化合物
AU2012225232B2 (en)	2011-03-09	2016-05-12	Richard G. Pestell	Prostate cancer cell lines, gene signatures and uses thereof
CA2846496C (en)	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP6518585B2 (ja)	2012-05-14	2019-05-22	リチャードジー．ペステル	がんの治療のためのｃｃｒ５の修飾薬の使用
JP2015532287A (ja)	2012-09-26	2015-11-09	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｉｒｅ１の調節
WO2014145576A2 (en)	2013-03-15	2014-09-18	Northwestern University	Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
CN108064274A (zh)	2014-07-30	2018-05-22	耶达研究及发展有限公司	用于培养多能干细胞的培养基
WO2017027883A1 (en)	2015-08-13	2017-02-16	San Diego State University Research Foundation	Atropisomerism for increased kinase inhibitor selectivity
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
AU2017362350B2 (en)	2016-11-18	2021-12-23	Cystic Fibrosis Foundation	Pyrrolopyrimidines as CFTR potentiators
US11602534B2 (en)	2017-12-21	2023-03-14	Hefei Institutes Of Physical Science, Chinese Academy Of Sciences	Pyrimidine derivative kinase inhibitors
CA3121202A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
EP3914698B1 (de)	2019-01-23	2024-12-11	Yeda Research and Development Co. Ltd	Kulturmedien für pluripotente stammzellen
US20220372040A1 (en) *	2019-10-25	2022-11-24	Accent Therapeutics, Inc.	Mettl3 modulators
WO2021097256A1 (en)	2019-11-14	2021-05-20	Cohbar, Inc.	Cxcr4 antagonist peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung

1995
- 1995-09-08 US US08/793,313 patent/US5869485A/en not_active Expired - Lifetime
- 1995-09-08 JP JP51131296A patent/JP4145955B2/ja not_active Expired - Fee Related
- 1995-09-08 DE DE69520282T patent/DE69520282T2/de not_active Expired - Lifetime
- 1995-09-08 EP EP95932693A patent/EP0783505B1/de not_active Expired - Lifetime
- 1995-09-08 HU HU9701333A patent/HU222181B1/hu not_active IP Right Cessation
- 1995-09-08 ES ES95932693T patent/ES2157344T3/es not_active Expired - Lifetime
- 1995-09-08 AU AU35643/95A patent/AU694801B2/en not_active Ceased
- 1995-09-08 AT AT95932693T patent/ATE199553T1/de not_active IP Right Cessation
- 1995-09-08 BR BR9509048A patent/BR9509048A/pt not_active IP Right Cessation
- 1995-09-08 WO PCT/EP1995/003536 patent/WO1996010028A1/en not_active Ceased
- 1995-09-08 DK DK95932693T patent/DK0783505T3/da active
- 1995-09-08 CA CA002200210A patent/CA2200210A1/en not_active Abandoned
- 1995-09-08 CN CN95196308A patent/CN1046731C/zh not_active Expired - Fee Related
- 1995-09-08 KR KR1019970702044A patent/KR970706288A/ko not_active Abandoned
- 1995-09-08 MX MX9702307A patent/MX9702307A/es not_active IP Right Cessation
- 1995-09-08 PT PT95932693T patent/PT783505E/pt unknown
- 1995-09-08 NZ NZ293249A patent/NZ293249A/en active IP Right Revival
1997
- 1997-03-21 NO NO971342A patent/NO308108B1/no not_active IP Right Cessation
- 1997-03-24 FI FI971225A patent/FI112867B/fi active
2001
- 2001-06-06 GR GR20010400849T patent/GR3035996T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ293249A (en)	1999-04-29
JPH10506624A (ja)	1998-06-30
KR970706288A (ko)	1997-11-03
PT783505E (pt)	2001-08-30
CA2200210A1 (en)	1996-04-04
CN1046731C (zh)	1999-11-24
AU694801B2 (en)	1998-07-30
EP0783505B1 (de)	2001-03-07
AU3564395A (en)	1996-04-19
JP4145955B2 (ja)	2008-09-03
NO971342D0 (no)	1997-03-21
HUT76785A (en)	1997-11-28
FI971225L (fi)	1997-05-14
DE69520282T2 (de)	2001-08-09
ES2157344T3 (es)	2001-08-16
CN1164234A (zh)	1997-11-05
NO971342L (no)	1997-03-21
GR3035996T3 (en)	2001-09-28
DE69520282D1 (de)	2001-04-12
FI971225A0 (fi)	1997-03-24
DK0783505T3 (da)	2001-07-02
BR9509048A (pt)	1998-01-06
NO308108B1 (no)	2000-07-24
EP0783505A1 (de)	1997-07-16
FI112867B (fi)	2004-01-30
HU222181B1 (hu)	2003-04-28
WO1996010028A1 (en)	1996-04-04
US5869485A (en)	1999-02-09
MX9702307A (es)	1998-04-30

Legal Events

Date	Code	Title	Description
2001-08-15	UEP	Publication of translation of european patent specification
2011-06-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE199553T1 (de)	2001-03-15	Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung
NO951684L (no)	1995-11-06	Pyrrolopyrimidinderivater med farmakologisk aktivitet
CY1105618T1 (el)	2010-12-22	Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης
MY134848A (en)	2007-12-31	Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
ES2193362T3 (es)	2003-11-01	Derivados de 2-pirimidinamina y su procedimiento de preparacion de los mismos.
DK0938486T3 (da)	2008-07-07	Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
DE69926542D1 (de)	2005-09-08	Aminopyrazol derivate
DE69709624D1 (de)	2002-02-21	Chinazolinverbindungen
EA200000842A1 (ru)	2001-04-23	Бицикло [2.2.1] гептаны и родственные соединения
TR199900048T2 (xx)	1999-04-21	Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
ATE454375T1 (de)	2010-01-15	1-phenyl-benzimidazolverbindungen und ihre verwendung als modulatoren des gaba-a-rezeptors
DE60236600D1 (de)	2010-07-15	Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
DE69507505D1 (de)	1999-03-04	Anilin derivate
NO975956D0 (no)	1997-12-18	Pyrrolopyrimidiner og fremgangsmåter for deres fremstilling
EA200400475A1 (ru)	2004-08-26	Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
MXPA05010975A (es)	2005-11-28	Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
DK0526588T3 (da)	1994-08-22	Heterocykliske forbindelser, deres fremstilling og anvendelse
ATE150751T1 (de)	1997-04-15	Neuroprotektive 3,4-dihydro-2(1h)-chinolone
DK63382A (da)	1982-02-12	Fremgangsmaade til fremstilling af diphenylbutyl-l-acylpiperaziner
UY26866A1 (es)	2001-09-28	Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenilpirido (2,3-d) pirimidin-7-onas
ATE193705T1 (de)	2000-06-15	4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen- - on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie
UA87895C2 (en)	2009-08-25	Substituted 5-phenyl pyrimidines i in therapy
ES2193047T3 (es)	2003-11-01	(3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.
ES530878A0 (es)	1985-05-16	Un procedimiento para la preparacion de nuevos derivados de aminoeticpiridina o pirazina.
EA200400560A1 (ru)	2004-12-30	ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4H-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-КАРБОКСАМИДА, ИХ ПОЛУЧЕНИЕ И ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ